Recommended for you
- Solutions
- Software
- Featured software:
- Software by solutionRegulatory Discovery Preclinical Early Clinical Late Clinical Market Access & Commercial View software
- Services
- Services by solutionRegulatory Discovery Preclinical Early Clinical Late Clinical Market Access & Commercial View services
- Customers
- Resources
- Featured resources:
- Resources by solutionRegulatory Discovery Preclinical Early Clinical Late Clinical Market Access & Commercial View all resources
- Company
search
Home / Poster / Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese
Application of a physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) model for prediction of drug-drug interactions (DDIs) involving the JAK1/2 inhibitor Ruxolitinib in Caucasians and Japanese
Newsletter sign up
Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.
Solutions
© 2025 Certara. All Rights Reserved. | Privacy policy